Denali Therapeutics Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Denali Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2024.
  • Denali Therapeutics Inc. Debt-to-equity for the quarter ending September 30, 2024 was 9.62 %, a 62.2% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 9.62 -15.8 -62.2% Sep 30, 2024
Q2 2024 9.67 -25.2 -72.2% Jun 30, 2024
Q1 2024 10.1 -35.3 -77.7% Mar 31, 2024
Q4 2023 18.7 -26.3 -58.5% Dec 31, 2023
Q3 2023 25.5 -21.2 -45.5% Sep 30, 2023
Q2 2023 34.8 -9.93 -22.2% Jun 30, 2023
Q1 2023 45.5 +2.11 +4.87% Mar 31, 2023
Q4 2022 45 +2.63 +6.21% Dec 31, 2022
Q3 2022 46.7 +5.88 +14.4% Sep 30, 2022
Q2 2022 44.8 +8.64 +23.9% Jun 30, 2022
Q1 2022 43.4 +9.6 +28.4% Mar 31, 2022
Q4 2021 42.4 +11.9 +39.2% Dec 31, 2021
Q3 2021 40.8 +13.2 +47.8% Sep 30, 2021
Q2 2021 36.1 +3.21 +9.76% Jun 30, 2021
Q1 2021 33.8 -0.55 -1.6% Mar 31, 2021
Q4 2020 30.4 -4.95 -14% Dec 31, 2020
Q3 2020 27.6 -2.86 -9.39% Sep 30, 2020
Q2 2020 32.9 +6.86 +26.3% Jun 30, 2020
Q1 2020 34.3 +12.5 +57.1% Mar 31, 2020
Q4 2019 35.4 +17.9 +103% Dec 31, 2019
Q3 2019 30.5 +17.1 +128% Sep 30, 2019
Q2 2019 26 Jun 30, 2019
Q1 2019 21.9 Mar 31, 2019
Q4 2018 17.4 Dec 31, 2018
Q3 2018 13.3 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.